Login / Register


Password: [Lost?]

New User? Click here for your FREE subscription

School and Community Healthcare Professionals
School and Community Healthcare Professionals Post a healthcare recruiting ad

Follow Us

NEWS-Line on Twitter NEWS-Line on Facebook NEWS-Line on Google+ NEWS-Line on LinkedIn NEWS-Line on Pinterest

School and Community Healthcare Conferences &
Educational Opportunities

Are Cannabis Products Safe And Effective For Reducing Symptoms In Children With Cancer? | NEWS-Line for Physical Therapists & PT Assistants

Are Cannabis Products Safe And Effective For Reducing Symptoms In Children With Cancer?


A recent analysis of all relevant published studies reveals a lack of evidence to determine the dosing, safety, and efficacy of medical marijuana or cannabis-containing products for managing symptoms experienced by children with cancer. The analysis is published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.

Although treatments for childhood cancer have improved significantly, even leading to cures for many patients, many children still suffer from symptoms such as pain, anxiety, and weight loss related to cancer and its treatment. Over the last decade, cannabis products—both synthetic cannabinoids and natural phytocannabinoids—have gained popularity with patients and families for managing such symptoms, but pediatric oncologists are cautious to authorize cannabis for their patients given the limited data to inform dosing, product selection, and safety monitoring.

To provide insights for clinicians and parents, and to inform an upcoming clinical trial, a team led by Lauren E. Kelly, PhD, associate professor of pharmacology and therapeutics in the Rady Faculty of Health Sciences at the University of Manitoba, searched the medical literature to summarize existing knowledge about the potential benefits and harms of cannabis products in children with cancer.

The investigators identified 19 unique studies with a total of 1,927 participants with cancer: eight retrospective chart reviews, seven randomized controlled trials, two open‐label studies, and two case reports. The products studied included medical-grade cannabinoids (such as the prescription drug nabilone), synthetic cannabinoids, and unspecified cannabis herbal extracts. Products were most commonly used to manage chemotherapy‐induced nausea and vomiting.

In the randomized controlled trials, patients who used cannabinoids were more likely to experience drowsiness, feeling high, dizziness, and dry mouth. Also, trial participants who received cannabinoids were almost four times more likely to drop from the study due to adverse events, compared with the control group who received placebo. Across all included studies, no serious cannabis‐related adverse events were reported.

Dr. Kelly and her colleagues noted that most studies did not adequately describe the types, dosing, frequencies, and routes of administration of cannabis products, and outcomes were mixed and were reported in different ways. Therefore, researchers should develop standards for reporting cannabis exposures, cannabis‐related effects, and patient outcomes.

“It was difficult to measure benefit across studies, given a range of different outcomes and study designs; however, in interventional studies with active control groups, cannabinoids performed better in managing nausea and vomiting. Data are lacking on cannabinoids’ effects on pain, mood, sleep, and health-related quality of life,” said Dr. Kelly. “Given that some children report benefits and some children experience adverse events, it is critical that more rigorous studies evaluating the effects of cannabinoids on children with cancer are conducted and shared with parents, patients, and the health care community.”

This literature review informed the design of CANnabinoids in Pediatric ONCology (CAN-PONC), which will begin recruiting 60 patients into a three-arm tolerability trial later this winter. The literature review and clinical trial are part of a team grant funded by the Canadian Cancer Society and Canadian Institutes of Health Research through a Cannabis Team Grant.

Additional information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. A free abstract of this article will be available via the CANCER Newsroom upon online publication. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, [email protected].

Full Citation:
“Cannabinoids for symptom management in children with cancer: A systematic review and meta‐analysis.” Manik Chhabra, Mohamed Ben‐Eltriki, Arun Paul, Mê‐Linh Lê, Anthony Herbert, Sapna Oberoi, Natalie Bradford, Alison Bowers, S. Rod Rassekh, and Lauren E. Kelly. CANCER; Published Online: August 28, 2023 (DOI: 10.1002/cncr.34920).
URL Upon Publication: http://doi.wiley.com/10.1002/cncr.34920

Author Contact: Ilana Simon, Director of Communications & Marketing, Rady Faculty of Health Sciences, University of Manitoba, [email protected]

About the Journal
CANCER  is a peer-reviewed publication of the American Cancer Society integrating scientific information from worldwide sources for all oncologic specialties. The objective of  CANCER  is to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology, course, and treatment of human cancer.  CANCER  is published on behalf of the American Cancer Society by Wiley and can be accessed online. Follow CANCER on Twitter @JournalCancer and Instagram @ACSJournalCancer, and stay up to date with the American Cancer Society Journals on LinkedIn.

About Wiley
Wiley is a knowledge company and a global leader in research, publishing, and knowledge solutions. Dedicated to the creation and application of knowledge, Wiley serves the world’s researchers, learners, innovators, and leaders, helping them achieve their goals and solve the world's most important challenges. For more than two centuries, Wiley has been delivering on its timeless mission to unlock human potential. Visit us at Wiley.com Follow us on Facebook,  Twitter, LinkedIn  and  Instagram

Source: CANCER

Post not cached because it doesn't exist

Share This!

School and Community Healthcare Jobs

Occupational Therapist

Helena Public Schools
Helena, Montana

Developmental Interventionist, Early Intervention - Part Time - Hourly pay rate: $57.51

The Arc of Union County
Springfield, New Jersey


Shield Institute
Bayside, New York

Occupational Therapist - I/DD Opportunity

Shield Institute
Bayside, New York

Director, Healthcare Supports, Clinical - Full Time 40 hrs - Salary $95,000

The ARC of Union County
Springfield, New Jersey

Smart Start Enrichment Program - Lead Teacher - 4 Month Job Assignment - $30/hr.

The ARC of Union County
Springfield, New Jersey

More Jobs
(Dismiss) Thank you for visiting NEWS-Line! Please sign up, login, or follow us on your favorite social networks
to receive custom tailored eNews, job listings, and educational opportunities for your specific profession.